Liminatus Pharma, Inc.
LIMN
$0.65
-$0.06-8.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -752.06% | -71,233.33% | 99.87% | 61.92% | 77.85% |
| Total Depreciation and Amortization | -28.57% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 186.90% | -- | -- | -- | -- |
| Change in Net Operating Assets | 101.59% | -2,497,833.33% | -99.66% | -77.74% | -75.46% |
| Cash from Operations | 93.31% | -- | 100.00% | 31.59% | 81.34% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | 31.25% | 46.67% |
| Cash from Investing | 98.31% | -- | -- | 31.25% | 46.67% |
| Total Debt Issued | -100.00% | -- | -- | -28.79% | -56.12% |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | 200.00% |
| Cash from Financing | -100.00% | -- | -- | -31.31% | -53.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.87% | -- | -- | -30.23% | 103.22% |